查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1996526

失智症治療市場：2026-2032年全球市場預測（按藥物類別、治療方法、給藥途徑、患者年齡層、疾病階段、專利狀態、分銷管道和最終用戶分類）

Dementia Drugs Market by Drug Class, Treatment Type, Route Of Administration, Patient Age Group, Disease Stage, Patent Status, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，失智症治療市場價值將達到 119.6 億美元，到 2026 年將成長至 132.8 億美元，到 2032 年將達到 263.9 億美元，複合年成長率為 11.96%。

主要市場統計數據
基準年 2025 119.6億美元
預計年份：2026年 132.8億美元
預測年份 2032 263.9億美元
複合年成長率 (%) 11.96%

對當前失智症治療現狀進行全面概述，將科學進步、患者照護現實和分配複雜性聯繫起來。

失智症治療領域正處於一個轉折點，新的科學發現、不斷發展的護理模式以及為患者和看護者帶來切實療效的日益成長的壓力共同塑造了這一局面。儘管我們對此疾病生物學機制的理解不斷加深，拓展了正在研究的治療標靶範圍，但現有的症狀治療在目前的臨床實踐中仍然至關重要。這些並行發展的趨勢要求相關人員既關注短期病患管理，也要關注長期創新路徑。

對重塑失智症治療研究、商業化、診斷和供應鏈方法的關鍵變革性變化進行詳細檢驗。

近年來，失智症治療領域發生了翻天覆地的變化，其影響範圍和程度都發生了根本性的轉變，改變了研究的優先順序和治療的實施方式。基於生物標記的診斷和認知衰退的早期檢測正在改變干預措施的合格標準，並使更有針對性的治療方法成為可能。診斷準確性的提高與不斷發展的臨床終點相互作用，促使研發人員重新思考臨床試驗設計和核准後證據的構建，以證明治療對患者及其看護者的實際益處。

分析概述了近期美國關稅政策如何影響整個失智症護理過程中的藥品採購、生產決策和分銷韌性。

美國貿易和關稅政策的變化正在為全球失智症藥物的生產和分銷帶來新的格局，其累積效應影響著製造、採購和分銷管道的運作。某些醫藥原料進口關稅的提高凸顯了供應商多元化和在地化生產的重要性，迫使企業評估將關鍵生產過程遷回本國或外包至鄰國的成本和戰略意義。這些調整也對下游相關人員，包括經銷商和終端用戶，產生了連鎖反應。

我們深入探索基於細分市場的治療領域、分銷管道、護理環境和患者群體等方面的見解，以促進臨床和商業策略的發展。

細分市場層面的趨勢揭示了不同治療領域、通路、醫療機構和患者特徵所面臨的不同挑戰，這些挑戰都為藥物研發和商業化策略提供了新的視角。膽鹼酯酶抑制劑和NMDA受體拮抗劑等藥物類別在症狀管理中繼續發揮核心作用，而多奈哌齊和美Memantine等藥物的聯合治療則展示瞭如何利用互補的作用機制來增強臨床療效。在膽鹼酯酶抑制劑中，多奈哌齊、Galantamine和Rivastigmine等藥物仍在進行劑量最佳化、耐受性和製劑改進的評估。

全面的區域分析揭示了不同的監管環境、支付方趨勢和製造地如何影響世界各地的醫療服務取得和交付。

區域趨勢是失智症治療藥物研發、核准和推廣的關鍵因素，每個地區都有其獨特的法規、付款者和醫療服務體系，這些都會影響策略選擇。在美洲，公共和私人支付方對報銷途徑有著強大的影響力，而對臨床試驗網路和生產製造的相對集中投資則支持了創新和快速商業化。該地區醫療基礎設施的多樣性要求採用高度靈活的分銷模式，以滿足都市區醫院和社區護理的需求。

對企業層面的策略性措施進行深入分析，這些措施結合了投資組合多元化、夥伴關係、供應鏈改進和真實世界數據 (REW) 計劃，以保持競爭優勢。

失智症治療領域中主要企業的策略重點在於產品組合多元化、策略聯盟以及生命週期管理的整合方法，以應對競爭壓力和臨床複雜性。這些企業若能平衡對症治療、聯合治療和新型作用機制的投資，就能更能滿足患者的多元需求，同時規避風險。與學術機構、生物技術創新者和契約製造組織 (CMO) 的合作正日益普遍，成為加速研發、擴大生產能力和保障供應鏈的手段。

為產業領導者提供切實可行的策略建議，以協調研究重點、供應鏈韌性、商業化方法和以患者為中心的服務模式。

產業領導者應採取多管齊下的策略，將研發重點與商業性需求和以病人為中心的護理路徑結合。優先發展生物標記驅動的研發和適應性試驗設計，可以加速識別最有可能獲益的患者群體；同時，對真實世界數據（REW）項目的同步投資，則能增強對支付方和醫療服務提供者的價值證明。將患者和看護者的見解融入產品設計和服務模式，可以提高用藥依從性，並帶來更佳的臨床療效。

對一種透明且嚴謹的調查方法的說明，該方法結合了相關人員訪談、文獻整合、情境測試和細分映射，以檢驗研究結果和意義。

本分析的調查方法結合了定性和定量方法，以確保獲得平衡的見解和可靠的檢驗。主要資料來源包括對臨床醫生、藥劑師、支付方代表和供應鏈專家的結構化訪談，以了解治療應用、分銷挑戰和獲取限制等方面的實際觀點。次要資料來源包括同儕審查文獻、監管指導文件和已發表的臨床試驗結果，以闡明科學和政策趨勢的背景。

簡要概述了戰略挑戰，重點強調整合科學進步、持續供應和以患者為中心的實施，以改善護理結果。

總之，目前失智症的治療現況既有延續性也有變革性。儘管診斷技術的進步和新策略正在重塑長期的創新路徑，但現有的症狀治療仍具有重要的臨床意義。相關人員必須平衡有針對性的研發、實證醫學的累積以及對服務模式的投資，以滿足病患的即時管理需求，同時也要兼顧保險公司、醫療服務提供者和看護者不斷變化的期望。成功取決於將嚴謹的科學研究與切實可行的營運計劃結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：失智症治療市場：依藥物類別分類

  • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • Galantamine
    • Rivastigmine

第9章：依治療方法失智症治療市場

  • 聯合治療
  • 單藥治療

第10章：失智症治療市場：依給藥途徑分類

  • 口服
  • 經皮

第11章：依患者年齡層分類的失智症治療藥物市場

  • 65-74歲
  • 75-84歲
  • 85歲或以上
  • 65歲以下

第12章 依疾病階段失智症治療藥物市場

  • 溫和的
  • 緩和
  • 嚴重

第13章：依專利狀況分類的失智症治療藥物市場

  • 品牌商品
  • 非專利的

第14章失智症治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第15章失智症治療市場：依最終用戶分類

  • 診所
  • 居家照護設施
  • 醫院
  • 護理機構

第16章失智症治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章失智症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章失智症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國失智症治療市場

第20章：中國失智症治療市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AC Immune SA
  • AstraZeneca plc
  • Axsome Therapeutics, Inc.
  • Cassava Sciences, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
Product Code: MRR-FD3F12D54013

The Dementia Drugs Market was valued at USD 11.96 billion in 2025 and is projected to grow to USD 13.28 billion in 2026, with a CAGR of 11.96%, reaching USD 26.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.96 billion
Estimated Year [2026] USD 13.28 billion
Forecast Year [2032] USD 26.39 billion
CAGR (%) 11.96%

A comprehensive introductory perspective on the current dementia drug environment that bridges scientific progress, patient care realities, and distribution complexities

The therapeutic landscape for dementia drugs is at an inflection point, shaped by new scientific insights, evolving care models, and intensifying pressure to deliver meaningful outcomes for patients and caregivers. Advances in understanding disease biology have broadened the range of therapeutic targets under investigation, while established symptomatic treatments remain critical to current clinical practice. These parallel trajectories demand that stakeholders maintain a dual focus on near-term patient management and longer-term innovation pathways.

Patient demographics and care delivery realities are creating added complexity for developers and providers. Diverse end users such as clinics, home care settings, hospitals, and long-term care facilities require flexible treatment options that accommodate different care capacities and administration settings. Distribution channels likewise span hospital pharmacy, online pharmacy, retail pharmacy, and specialty pharmacy, adding layers to commercialization strategies and patient access planning.

Therapeutic choices are informed by treatment type distinctions between combination therapy and monotherapy, and by route of administration considerations such as oral and transdermal options. Drug class segmentation-including cholinesterase inhibitors and NMDA receptor antagonists-continues to underpin many prescribing decisions, while combination approaches aim to improve symptom control and patient functionality. As the ecosystem adapts, stakeholders will need integrated strategies that reconcile scientific advances with practical constraints in care delivery and distribution.

A detailed examination of the major transformative shifts reshaping research, commercialization, diagnostics, and supply chain approaches in dementia therapeutics

Recent shifts in the dementia drugs landscape are transformative in both scope and implication, altering how research is prioritized and how treatments are delivered. Biomarker-driven diagnostics and earlier identification of cognitive decline are changing the eligibility criteria for interventions and enabling more targeted therapeutic approaches. This diagnostic precision interacts with evolving clinical endpoints, prompting developers to recalibrate trial designs and post-approval evidence generation to demonstrate tangible benefits for patients and caregivers.

Commercially, the balance between branded innovation and generic competition is changing how companies plan lifecycle strategies, with patent status and formulation options shaping product longevity. Digital therapeutics and remote monitoring tools are beginning to complement pharmacologic regimens, extending the role of telehealth and digital adherence programs into chronic management pathways. These shifts are also affecting distribution channels and end-user interactions, as online pharmacy services and specialty pharmacy models grow in relevance for complex or high-cost therapies.

Operationally, supply chain resilience and geographic manufacturing strategies have become strategic differentiators. Companies are reassessing sourcing for active pharmaceutical ingredients, investing in regional manufacturing capacity, and forging partnerships to secure continuity of supply. Concurrently, payer expectations are driving more rigorous value demonstration and real-world evidence collection, linking reimbursement and access to demonstrable patient outcomes and economic impact.

An analytical overview of how recent United States tariff policies are influencing pharmaceutical sourcing, manufacturing decisions, and distribution resilience across the dementia care continuum

Policy changes in trade and tariffs enacted in the United States have introduced new dynamics into the global production and distribution of dementia therapies, and the cumulative effects extend across manufacturing, procurement, and channel operations. Higher import duties on certain pharmaceutical inputs have increased the importance of supplier diversification and of localized manufacturing, prompting companies to evaluate the cost and strategic implications of reshoring or nearshoring key production steps. These adjustments have ripple effects for downstream stakeholders, including distributors and end users.

Distribution channels such as hospital pharmacy, specialty pharmacy, retail pharmacy, and online pharmacy are responding to altered cost structures and lead times. Hospitals and long-term care facilities that rely on stable supply chains may experience procurement challenges or need to renegotiate terms with suppliers. Specialty pharmacies, which often manage complex therapies and limited distribution products, are particularly sensitive to cost pass-through and logistical disruptions, and may shift sourcing strategies to mitigate exposure.

The tariffs context also affects branded and generic product strategies differently. Manufacturers of branded therapies may accelerate efforts to protect supply continuity for premium products, while generic manufacturers could face margin compression that influences production decisions. For multinational companies, regional manufacturing footprints and third-party logistics partnerships have emerged as critical levers to absorb trade policy shocks and maintain uninterrupted access for patients across care settings.

A thorough exploration of segmentation-driven insights across therapeutic class, distribution channels, care settings, and patient cohorts that inform clinical and commercial strategy

Segment-level dynamics reveal differentiated imperatives across therapeutic class, distribution pathway, care setting, and patient characteristics, each carrying implications for development and commercialization strategies. Drug classes such as cholinesterase inhibitors and NMDA receptor antagonists remain central to symptomatic management, while combination therapies that pair agents like donepezil and memantine illustrate how complementary mechanisms are being deployed to enhance clinical benefit. Within cholinesterase inhibitors, agents including donepezil, galantamine, and rivastigmine continue to be evaluated for optimized dosing, tolerability, and formulation improvements.

Distribution channels shape access and patient experience, with hospital pharmacy environments prioritizing inpatient continuity of care, retail pharmacy supporting routine outpatient dispensing, specialty pharmacy delivering complex care coordination, and online pharmacy providing convenience and adherence supports. End users ranging from clinics to home care settings, hospitals, and long-term care facilities demand different formulations and packaging solutions, and they place varying emphasis on administration ease and monitoring requirements. Treatment type distinctions between combination therapy and monotherapy influence prescribing patterns and payer negotiations, particularly in populations with comorbidities.

Route of administration choices such as oral versus transdermal delivery influence adherence profiles, tolerability, and caregiver burden, while patient age group segmentation including cohorts under 65, 65 to 74, 75 to 84, and 85 and above highlights shifting clinical priorities and comorbidity considerations. Disease stage stratification across mild, moderate, and severe dementia informs therapeutic intent, care pathways, and clinical trial design. Patent status categories of branded and generic products continue to dictate competitive dynamics and lifecycle planning, reinforcing the need for flexible commercial models that anticipate transitions in exclusivity and pricing environment.

A comprehensive regional analysis revealing how differing regulatory landscapes, payer dynamics, and manufacturing footprints shape access and delivery across global territories

Regional dynamics are a defining factor in how dementia therapies are developed, approved, and deployed, and each geographic area presents distinct regulatory, payer, and care delivery realities that shape strategic choices. In the Americas, public and private payers exert strong influence over reimbursement pathways, and clinical trial networks and manufacturing investments are relatively concentrated, supporting both innovation and rapid commercialization. Healthcare infrastructure diversity within the region necessitates adaptable distribution models that can meet the needs of urban hospitals and community-based care alike.

Across Europe, the Middle East and Africa, regulatory heterogeneity and varying levels of healthcare resourcing create complex market entry considerations. Pricing and reimbursement frameworks across European countries often emphasize comparative effectiveness and health technology assessment, prompting developers to invest in outcomes research and real-world evidence generation. In the MEA region, access considerations and capacity constraints influence adoption timelines, while partnerships with regional distributors and local manufacturers can improve supply reliability and patient reach.

Asia-Pacific exhibits significant heterogeneity in regulatory pathways, demographic trends, and manufacturing capacity. Several countries in the region serve as major manufacturing hubs for active pharmaceutical ingredients and finished formulations, while neighbouring markets present substantial demand driven by aging populations and expanding healthcare access. Companies operating in this region must navigate variable reimbursement systems, local clinical practice preferences, and opportunities for collaboration with regional research institutions to accelerate development and access.

An incisive review of company-level strategic moves that combine portfolio diversification, partnerships, supply chain fortification, and real-world evidence efforts to sustain competitive advantage

Key company strategies in the dementia therapeutics domain emphasize diversified portfolios, strategic partnerships, and an integrated focus on lifecycle management to navigate competitive pressures and clinical complexity. Firms that balance investment across symptomatic agents, combination therapies, and novel mechanisms can better address heterogeneous patient needs while hedging risk. Collaboration with academic centers, biotech innovators, and contract manufacturing organizations is increasingly common as a route to accelerate development, expand manufacturing capacity, and secure supply chains.

Commercial tactics include targeted engagement with specialty pharmacies and long-term care providers to optimize distribution for patients with advanced care needs, while retail and online pharmacy channels are leveraged to enhance outpatient adherence and caregiver convenience. Companies are also prioritizing outcomes and real-world data initiatives to demonstrate value to payers and health systems, supporting reimbursement discussions and formulary positioning. For organizations facing patent transitions, strategies such as reformulation, delivery innovations like transdermal patches, and indication expansion are being used to preserve therapeutic relevance.

Leadership teams are investing in digital capabilities to complement pharmacologic treatment, including adherence platforms and remote monitoring, which can strengthen value propositions for payers and providers. Additionally, firms are increasingly focused on geographic diversification of manufacturing and clinical trial enrollment to manage regulatory risk and to accelerate access across multiple regions.

Actionable strategic recommendations for industry leadership that align research priorities, supply chain resilience, commercialization approaches, and patient-centered service models

Industry leaders should adopt a multi-dimensional strategy that aligns R&D priorities with commercial imperatives and patient-centered care pathways. Prioritizing biomarker-enabled development and adaptive trial designs can accelerate identification of populations most likely to benefit, while parallel investment in real-world evidence programs will strengthen value demonstration for payers and providers. Integrating patient and caregiver insights into product design and service models enhances adherence and supports superior clinical outcomes.

Operational resilience requires proactive supply chain diversification, including assessment of alternative API suppliers, consideration of regional manufacturing footprints, and partnerships with logistics providers to manage tariff and trade uncertainties. Commercially, organizations should tailor distribution strategies to distinct channel characteristics-hospital pharmacy, retail pharmacy, specialty pharmacy, and online pharmacy-ensuring that logistical capabilities match product complexity and patient needs. Collaboration with long-term care facilities, hospitals, clinics, and home care providers is essential to streamline adoption and to address site-specific training and support requirements.

Finally, leaders should pursue value-based contracting pilots and outcomes-linked arrangements where feasible, pairing these with digital health solutions that monitor adherence and functional outcomes. This combination can reduce payer resistance, de-risk adoption, and create pathways for sustained access while demonstrating a commitment to improving patient quality of life.

A transparent and rigorous description of methodology combining stakeholder interviews, literature synthesis, scenario testing, and segmentation mapping to validate findings and implications

The research methodology underpinning this analysis blended qualitative and quantitative approaches to ensure balanced insight and robust validation. Primary inputs included structured interviews with clinicians, pharmacists, payer representatives, and supply chain experts to capture frontline perspectives on therapeutic use, distribution challenges, and access constraints. Secondary sources encompassed peer-reviewed literature, regulatory guidance documents, and published clinical trial results to contextualize scientific and policy developments.

Analytical steps involved triangulating stakeholder inputs with literature findings to identify consistent themes and to reconcile divergent views. Scenario analysis was applied to stress-test supply chain and commercial strategies under different trade and regulatory conditions. In addition, segmentation maps were constructed to illuminate how drug class, distribution channel, end-user setting, treatment type, route of administration, patient age group, disease stage, and patent status interact to influence clinical and commercial outcomes.

Quality assurance procedures included expert panel review and iterative validation cycles, ensuring that conclusions reflect practical realities and clinical plausibility. The methodology prioritized transparency and reproducibility, enabling decision makers to trace insights back to source inputs and to adapt analytical frameworks for organization-specific use cases.

A concise summation of strategic imperatives that emphasizes the integration of scientific advancement, supply continuity, and patient-centered execution to improve care outcomes

In conclusion, the dementia therapeutics landscape is characterized by simultaneous continuity and change: established symptomatic agents retain clinical importance even as diagnostic advances and novel strategies reshape long-term innovation pathways. Stakeholders must balance immediate patient management needs with investments in targeted R&D, evidence generation, and delivery models that meet the evolving expectations of payers, providers, and caregivers. Success will depend on aligning scientific rigor with pragmatic operational planning.

Supply chain resilience, adaptive commercialization approaches, and cross-sector partnerships will be key to sustaining access and to translating therapeutic progress into meaningful patient impact. Regional considerations, distribution channel dynamics, and segmentation nuances underscore the need for tailored strategies that respect local regulatory and care delivery contexts. By integrating clinical insight, real-world evidence, and patient-centered design, organizations can navigate complexity and contribute to improved outcomes for people living with dementia.

The path forward will require sustained collaboration across industry, clinical, and policy stakeholders to ensure that new and existing therapies reach the patients who need them most, while maintaining affordability and continuity of care across diverse settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dementia Drugs Market, by Drug Class

  • 8.1. Cholinesterase Inhibitors
    • 8.1.1. Donepezil
    • 8.1.2. Galantamine
    • 8.1.3. Rivastigmine

9. Dementia Drugs Market, by Treatment Type

  • 9.1. Combination Therapy
  • 9.2. Monotherapy

10. Dementia Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Transdermal

11. Dementia Drugs Market, by Patient Age Group

  • 11.1. 65 To 74
  • 11.2. 75 To 84
  • 11.3. 85 And Above
  • 11.4. Under 65

12. Dementia Drugs Market, by Disease Stage

  • 12.1. Mild
  • 12.2. Moderate
  • 12.3. Severe

13. Dementia Drugs Market, by Patent Status

  • 13.1. Branded
  • 13.2. Generic

14. Dementia Drugs Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy
  • 14.4. Specialty Pharmacy

15. Dementia Drugs Market, by End User

  • 15.1. Clinics
  • 15.2. Home Care Settings
  • 15.3. Hospitals
  • 15.4. Long-Term Care Facilities

16. Dementia Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Dementia Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Dementia Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Dementia Drugs Market

20. China Dementia Drugs Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AC Immune SA
  • 21.6. AstraZeneca plc
  • 21.7. Axsome Therapeutics, Inc.
  • 21.8. Cassava Sciences, Inc.
  • 21.9. Eisai Co., Ltd.
  • 21.10. Eli Lilly and Company
  • 21.11. F. Hoffmann-La Roche Ltd.
  • 21.12. H. Lundbeck A/S
  • 21.13. Johnson & Johnson
  • 21.14. Merck & Co., Inc.
  • 21.15. Novartis AG
  • 21.16. Otsuka Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GCC DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. G7 DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. NATO DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)